Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $8.50 to $10.26
• 50-Day Range: $7.00 to $12.86
• 52-Week Range: $4.88 to $19.58
• Volume: 146,968 shs
• Average Volume: 121,577 shs
• Market Capitalization: $189.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.50
• Consensus Rating: Buy

AARD Stock Analysis - Frequently Asked Questions

How have AARD shares performed this year?

Aardvark Therapeutics' stock was trading at $13.30 on January 1st, 2025. Since then, AARD stock has decreased by 34.3% and is now trading at $8.74.
View the best growth stocks for 2025 here.

How were Aardvark Therapeutics' earnings last quarter?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its earnings results on Wednesday, May, 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

When did Aardvark Therapeutics IPO?

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

When did the company's quiet period expire?

Aardvark Therapeutics' quiet period expired on Tuesday, March 25th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Aardvark Therapeutics' major shareholders?

Top institutional investors of Aardvark Therapeutics include Decheng Capital LLC (18.06%) and Walleye Capital LLC (0.05%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends.

How do I buy shares of Aardvark Therapeutics?

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/14/2025
• Last Earnings: 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.50
• High Stock Price Target: $50.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +260.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,696,000
• Free Float: N/A
• Market Cap: $189.62 million
• Optionable: N/A
• Beta: N/A